Charles River Laboratories International, Inc.
Location
Massachusetts
Founded
1947-02-28
Website
Risk Signals
1070 news mentions monitored
Industry Context
This company is tracked across risk categories, including those related to its sector (e.g., Commercial Physical and Biological Research, Testing Laboratories), including supply chain integrity, ESG practices, labor disputes, and regulatory compliance.
Filter risk signals by topic
Select a theme below to explore the company’s news mentions in specific risk areas.
Recent Articles about Charles River Laboratories International, Inc.
Live alerts from global media, monitored by Business Radar
2024-12-12 (market.us)
Clinical Trials Market To Grow At Steady 7.2% CAGR By 2032
Global Clinical Trials Market size is expected to be worth around US$ 886.5 Billion by 2032 from US$ 483 Billion in 2023
Read more
2022-09-26 (defenseworld.net)
State of Alaska Department of Revenue Grows Stock Position in Charles River Laboratories International, Inc. (NYSE:CRL)
State of Alaska Department of Revenue boosted its position in Charles River Laboratories International, Inc.( NYSE: CRL– Get Rating) by 2.6% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission(
Read more
2022-07-02 (ourcommunitynow.com)
State of Alaska Department of Revenue Lowers Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)
State of Alaska Department of Revenue lowered its position in shares of Charles River Laboratories International, Inc.( NYSE: CRL– Get Rating) by 2.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities
Read more
(morningstar.com)
Charles River Laboratories Announces Second-Quarter 2023 Results
Acquisitions contributed 0.2% to consolidated second-quarter revenue growth. The divestiture of the Avian Vaccine business in December 2022 reduced reported revenue growth by 2.3%, and the impact of foreign currency translation reduced reported revenue growth by 0.2% for the quarter. Excluding the
Read more
(morningstar.com)
Charles River Laboratories Announces First-Quarter 2023 Results
Acquisitions contributed 1.8% to consolidated first-quarter revenue growth, and the divestiture of the Avian Vaccine business in December 2022 reduced reported revenue growth by 2.5%. The impact of foreign currency translation reduced reported revenue growth by 2.1%. Excluding the effect of these
Read more